NTI — Neurotech International Share News
0.000.00%
Last trade - 00:00- AU$25.04m
- AU$22.65m
- AU$0.04m
Australia's Neurotech International jumps on FDA orphan tag for Rett Syndrome drug
Brief: Neurotech Appoints Anthony Filippis As CEO
Australia's Neurotech falls on drug request denial by U.S. FDA
Brief: Neurotech International Says U.S. FDA Declined Request For Orphan Drug Designation
Brief: Neurotech International Requests US FDA Orphan Drug Designation For Rett Syndrome
Brief: Neurotech International To Secure One Or More Strategic Partnerships
Australia's Neurotech International rises on positive results from autism therapy trial
Brief: Neurotech International Formalises Strategic Partnership With Fenix Innovation
Brief: Neurotech International Seeks Trading Halt
Brief: Neurotech International Completes A$10.0 Million Capital Raise
Brief: Neurotech International Says Neurotech Phase II/III Autism Trial Meets Primary Endpoint
Brief: Neurotech International Seeks Trading Halt
Brief: Neurotech International Says Strategic Partnership With Fenix Innovation Group
Brief: Neurotech International Seeks Trading Halt
Brief: Neurotech International Receives HREC Approval For Phase I/Ii Clinical Trial In Rett Syndrome
Brief: Neurotech International Seeks Trading Halt
Brief: Neurotech International Posts HY Loss After Income Tax Of A$3.5 Million
Australia's Neurotech jumps after getting U.S. FDA meeting approval
Brief: Neurotech International Granted U.S. FDA Pre-Ind Meeting For Nti164 In Autism Spectrum Disorder